MetaCap

IDEAYA Biosciences Inc. (IDYA)

NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

25.56-0.61 (-2.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IDYA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$4.50
52-week range
25.46 – 42.68
Day range
25.46 – 26.87
Volume / Avg
1.11M / 933.58K
Beta
—

52-week range

$25.46$42.68

IDYA stock today

IDEAYA Biosciences (IDYA) closed at $25.56 on Nov 20, down 2.33% (-$0.61), versus the S&P 500's 3.70% decline. Shares are 40.1% below their 52-week high of $42.68, set on Aug 25, 2026 and 0.4% above the 52-week low of $25.46, near the bottom of the past year's range. IDYA is down 26.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.8%.

IDEAYA Biosciences has posted a net loss over the last twelve months (EPS of -$4.50), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About IDEAYA Biosciences

Company profile

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Yujiro S. Hata
Headquarters
South San Francisco, CA
Employees
145
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, IDEAYA Biosciences generated $218.7 million in revenue, up 3024.4% from fiscal 2024. IDEAYA Biosciences reported a net loss of $113.7 million, compared with a loss of $274.5 million a year earlier. Operating margin was -72.8%.

IDEAYA Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$218.71M$7.00M$23.39M$50.93M$27.94M
Growth+3024.43%-70.07%-54.08%+82.28%+43.01%
Net income$-113.70M$-274.48M$-112.96M$-58.66M$-49.76M
EPS (diluted)$-1.28$-3.36$-1.96$-1.42$-1.41

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$50.69+98.32%

  • Strong buy 2
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $66.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 3, 2026
EPS actual vs est.
$-1.22 vs $-1.26
Surprise
+3.17%

IDYA news

All IDYA news

IDEAYA Biosciences peers

Health Care sector
IDYA peer companies
CompanyPrice% ChgMarket capCompare
MBXMBX Biosciences Inc.49.55-7.23%$2.46Bvs IDYA
XNCRXencor Inc.33.26-2.21%$2.50Bvs IDYA
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs IDYA
ZLABZai Lab Limited ADR21.03-4.06%$2.63Bvs IDYA
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs IDYA
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs IDYA
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs IDYA
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs IDYA

Indexes, lists and sector

IDEAYA Biosciences stock FAQ

What is IDEAYA Biosciences's stock price today?

IDYA last traded at $25.56 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.

Who is IDEAYA Biosciences's CEO?

Mr. Yujiro S. Hata is the chief executive officer of IDEAYA Biosciences Inc., which has about 145 employees.

What is the IDYA 52-week high?

The 52-week high for IDYA is $42.68 and the 52-week low is $25.46. The stock is currently 40.1% below its high.

Compare IDYA